Chronic venous disease and diabetic microangiopathy: pathophysiology and commonalities.


Journal

International angiology : a journal of the International Union of Angiology
ISSN: 1827-1839
Titre abrégé: Int Angiol
Pays: Italy
ID NLM: 8402693

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 23 9 2021
medline: 15 12 2021
entrez: 22 9 2021
Statut: ppublish

Résumé

Chronic venous disease and diabetes mellitus are highly prevalent and debilitating conditions affecting millions of individuals globally. Although these conditions are typically considered as separate entities, they often co-exist which may be important in both understanding their pathophysiology and determining the best treatment strategy. Diabetes mellitus is twice as common in patients with chronic venous disease compared with the general population. Notably, a large proportion of patients with diabetes mellitus present with venous disorders, although this is often overlooked. The etiology of chronic venous disease is multifactorial, involving hemodynamic, genetic, and environmental factors which result in changes to the venous endothelium and structural wall as well as inflammation. Inflammation, endothelial dysfunction and hyperfiltration or leakage, are commonly observed in diabetes mellitus and cause various diabetic microvascular complications. Both diseases are also influenced by the increased expression of adhesion molecules, chemokines, and cytokines, and are characterized by the presence of vessel hypertension. Consequently, despite differences in etiology, the pathophysiology of both chronic venous disease and diabetic microangiopathy appears to be driven by endothelial dysfunction and inflammation. Treatment strategies should take the co-existence of chronic venous disease and diabetic microangiopathy into account. Compression therapy is recommended in inflammatory conditions that have an edema component as seen in both chronic venous disease and diabetes mellitus. Lifestyle changes like weight loss and exercise, will improve metabolic state and lower inflammation and should be promoted in these patients. Additionally, both patient populations may benefit from venoactive drugs.

Identifiants

pubmed: 34547884
pii: S0392-9590.21.04664-2
doi: 10.23736/S0392-9590.21.04664-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-469

Auteurs

Giacomo Gastaldi (G)

Division of Endocrinology Diabetology Nutrition and Patient Education, Geneva University Hospitals, Geneva, Switzerland.

Felizitas Pannier (F)

Private Clinic Phlebology and Dermatology, Bonn, Germany.
Department of Dermatology, University of Cologne, Cologne, Germany.

Karel Roztočil (K)

Department of Transplantational and Vascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Marzia Lugli (M)

Unit of Vascular Surgery, Cardiovascular Department, Hesperia Hospital, Modena, Italy.

Armando Mansilha (A)

Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Angiology and Vascular Surgery, Hospital de S. João, Porto, Portugal.

Hermann Haller (H)

Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany.

Eberhard Rabe (E)

Department of Dermatology (Emeritus), University of Bonn, Bonn, Germany.

Marie Josee VAN Rijn (MJ)

Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, the Netherlands - m.vanrijn@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH